Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day

Author's Avatar
Mar 22, 2022

mRNA-1230 is a combination respiratory vaccine candidate against SARS-CoV-2 virus, influenza virus and respiratory syncytial virus (RSV)